Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Follow-On Biologics Would Save $71 Billion Over 10 Years, Express Scripts Estimates

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

The PBM report models savings stemming from the use of biosimilars for interferons, erythropoietin, growth hormone and insulin.

You may also be interested in...



Follow-on Biologics Get Modest Savings Score From CBO, Giving Legislation No Push

Congressional Budget Office projects follow-on products could capture 35 percent of market with 40 percent lower price tag.

Follow-on Biologics Get Modest Savings Score From CBO, Giving Legislation No Push

Congressional Budget Office projects follow-on products could capture 35 percent of market with 40 percent lower price tag.

Step Therapy Boosts Generic Lipid, Sleep Drugs Use

Express Scripts finds insurers cut costs by as much as 14 percent.

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By